Chinese Journal of Pharmacovigilance ›› 2014, Vol. 11 ›› Issue (1): 47-49.
• Orignal Article • Previous Articles Next Articles
YU Hao1, ZHOU Yong-gang2, *, LI Xiao-wei2, WANG You-qun1
Received:
2016-02-03
Revised:
2016-02-03
Online:
2014-01-08
Published:
2016-02-03
CLC Number:
YU Hao, ZHOU Yong-gang, LI Xiao-wei, WANG You-qun. Effect of Strengthened Drug Education by Clinical pharmacist on Survival, Rehospitalization and Reoperation Rate of Coronary Heart Disease Patients[J]. Chinese Journal of Pharmacovigilance, 2014, 11(1): 47-49.
[1] 王朝晖. 重视高龄老人冠心病诊治特点[J]. 临床心血管病杂志, 2012, 28(7): 481-483. [2] WHO. Global strategy on diet, physical activity and health[EB/OL].(2009-04-30)[2013-06-01].http://www.who.int/dietphysicalactivity/ goals/en/index.html. [3] 中华医学会心血管病学分会. 中国心血管病预防指南[J]. 中华心血管病杂志, 2011, 39(1): 3-22. [4] 王贵芝, 高鹤南, 熊薇, 等. 护士在冠心病二级预防中的作用[J]. 中华护理杂志, 2001, 36(7): 515-516. [5] Hymel P, Loeppke R, Baase C, et al. Establishing a research agenda in health and productivity[J]. Journal of Occupational and Environmental Medicine, 2004, 46(6): 518-520. [6] 蒙凯凤,黄萍.电话随访冠心病病人二级预防的效果分析[J]. 内科, 2008, 3(5): 812-813. [7] 姜风华,刘理慧, 姜光红.电话随访在中青年冠心病患者遵医行为中的作用[J]. 齐鲁护理杂志, 2009, 15(011): 16-18. [8] 陇文菊.电话回访式健康教育对老年冠心病患者生活质量的影响[J].中国老年学杂志, 2010, 30(7): 975-976. [9] Hwang S S, Barfield W D, Smith R A, et al. Discharge Timing, Outpatient Follow-up, and Home Care of Late-Preterm and Early-Term Infants[J]. Pediatrics, 2013 ,132(1):101-108. |
[1] | JIA Jinsheng, LIU Hongliang, WANG Qing, HOU Yongfang, LI Xinling. Evaluation of the relevance of adverse drug reaction based on ERNIE-DPCNN [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 163-166. |
[2] | MA Meiying, ZHAO Xiaopei, ZHANG Mengyao, HU Yilin. Drug traceability coding system in China [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 167-172. |
[3] | ZHU Ying, SHEN Lu, LI Lan, WU Jianmin, GAO Xiaojie. Adverse reaction monitoring of toothpaste in China under the new regulatory system [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 219-222. |
[4] | GAO Yunjuan, ZHAO Xu, BAI Tiankai, BAI Zhaofang, WANG Jiabo, SONG Haibo, XIAO Xiaohe. Discovery and identification strategy for drug safety risks based on big data monitoring of adverse reactions [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 1-5. |
[5] | MA Li’na, HU Xiaozhen, ZHENG Changhui, SUN Ying, ZHAO Xu, CAO Junling, XIAO Xiaohe. Visual analysis of knowledge map of toxic Chinese medicine Changshan toxicity-effect transformation based the thought of “yin du wei neng” [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 25-32. |
[6] | LIU Min, CHEN Yan, LIU Wendong, WANG Haixue. Updates and reflections on expedited reporting of safety information during drug clinical trials [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 98-101. |
[7] | TIAN Chunhua, WU Guizhi. Implementation of periodic benefit risk evaluation reports in China [J]. Chinese Journal of Pharmacovigilance, 2023, 20(12): 1382-1384. |
[8] | ZHAO Yan, LI Yao, SONG Ya’na, ZHENG Lijia, LI Dong, ZHAO Yifei, BIAN Rongrong, DONG Fang. Post-marketing active monitoring of medical devices under vigilance [J]. Chinese Journal of Pharmacovigilance, 2023, 20(12): 1385-1390. |
[9] | PANG Yu, LIU Bo, WU Wenyu, TIAN Yuejie, WANG Tao. Establishment of patient reporting scheme in the UK and its implications [J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1259-1263. |
[10] | WU Yunxiao, YU Yuelin, WANG Shengfeng, SUN Feng, MENG Ruogu, ZHAN Siyan. Suitability assessment of real-world data in active post-marketing surveillance of vaccine safety [J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1081-1089. |
[11] | JIA Jinsheng, WANG Qing, LIU Hongliang, HOU Yongfang. Evaluation index system of MAH pharmacovigilance work [J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1090-1094. |
[12] | LIU Hongliang, WANG Qing, HOU Yongfang. Design and implementation of polypharmacy risk data management platform for common diseases of the elderly based on real world data [J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1095-1098. |
[13] | XIA Xudong, LI Meixia, SUN Yang, YANG Shengya. Processes of remote inspection of pharmacovigilance for marketing authorization holders [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 967-970. |
[14] | LI Xiaozhu, WANG Qiang, PANG Yu, ZHANG Yijing. Management of individual adverse drug reaction reports [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 975-977. |
[15] | SHEN Yanjie, WU Yiqing. Management of adverse events during clinical trials [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 982-986. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||